8 [36] J. M. Neutel, “Eﬀect of the renin-angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function,” Journal of Human Hypertension, vol. 18, no. 9, pp. 599–606, 2004. [37] L. Gu, Y. Okada, S. K. Clinton et al., “Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deﬁcient mice,” Molecular Cell, vol. 2, no. 2, pp. 275–281, 1998. [38] Y. Han, M. S. Runge, and A. R. Brasier, “Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor- κb transcription factors,” Circulation Research, vol. 84, no. 6, pp. 695–703, 1999. [39] A. R. Brasier, A. Recinos, M. S. Eledrisi, and M. S. Runge, “Vascular inﬂammation and the renin-angiotensin system,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 8, pp. 1257–1266, 2002. [40] B. Williams, A. Q. Baker, B. Gallacher, and D. Lodwick, “Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells,” Hyper- tension, vol. 25, no. 5, pp. 913–917, 1995. [41] C. Cheng, D. Tempel, R. Van Haperen et al., “Atherosclerotic lesion size and vulnerability are determined by patterns of ﬂuid shear stress,” Circulation, vol. 113, no. 23, pp. 2744– 2753, 2006. [42] P. R. Moreno, K. R. Purushothaman, M. Sirol, A. P. Levy, and V. Fuster, “Neovascularization in human atherosclerosis,” Circulation, vol. 113, no. 18, pp. 2245–2252, 2006. [43] P. Dandona, S. Dhindsa, H. Ghanim, and A. Chaudhuri, “Angiotensin II and inﬂammation: the eﬀect of angiotensin- converting enzyme inhibition and angiotensin II receptor blockade,” Journal of Human Hypertension, vol. 21, no. 1, pp. 20–27, 2007. [44] J. I. Koga, K. Egashira, T. Matoba et al., “Essential role of angiotensin II type 1a receptors in the host vascular wall, but not the bone marrow, in the pathogenesis of angiotensin II- induced atherosclerosis,” Hypertension Research, vol. 31, no. 9, pp. 1791–1800, 2008. [45] Z. S. Galis and J. J. Khatri, “Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly,” Circulation Research, vol. 90, no. 3, pp. 251– 262, 2002. [46] J. Chen, D. Li, R. F. Schaefer, and J. L. Mehta, “Inhibitory eﬀect of candesartan and rosuvastatin on CD40 and MMPs expression in Apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis,” Journal of Cardiovascular Pharmacology, vol. 44, no. 4, pp. 446–452, 2004. [47] M. Luchtefeld, K. Grote, C. Grothusen et al., “Angiotensin II induces MMP-2 in a p47phox-dependent manner,” Biochem- ical and Biophysical Research Communications, vol. 328, no. 1, pp. 183–188, 2005. [48] H. Itoh, M. Mukoyama, R. E. Pratt, G. H. Gibbons, and V. J. Dzau, “Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II,” Journal of Clinical Investigation, vol. 91, no. 5, pp. 2268– 2274, 1993. [49] A. J. Naftilan, R. E. Pratt, and V. J. Dzau, “Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells,” Journal of Clinical Investigation, vol. 83, no. 4, pp. 1419–1424, 1989. [50] M. J. Pollman, T. Yamada, M. Horiuchi, and G. H. Gibbons, “Vasoactive substances regulate vascular smooth muscle cell Cardiology Research and Practice apoptosis: countervailing inﬂuences of nitric oxide and angiotensin II,” Circulation Research, vol. 79, no. 4, pp. 748– 756, 1996. [51] T. Takagishi, N. Murahashi, S. Azagami, M. Morimatsu, and Y. Sasaguri, “Eﬀect of angiotensin II and thromboxane A2 on the production of matrix metalloproteinase by human aortic smooth muscle cells,” Biochemistry and Molecular Biology International, vol. 35, no. 2, pp. 265–273, 1995. [52] T. Scott-Burden, A. W. A. Hahn, T. J. Resink, and F. R. Buh- ler, “Modulation of extracellular matrix by angiotensin II: stimulated glycoconjugate synthesis and growth in vascular smooth muscle cells,” Journal of Cardiovascular Pharmacol- ogy, vol. 16, supplement 4, pp. S36–S41, 1990. [53] R. M. Touyz, “Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II,” Experimental Physiology, vol. 90, no. 4, pp. 449–455, 2005. [54] R. M. Touyz and E. L. Schiﬀrin, “Signal transduction mech- anisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells,” Pharmacological Reviews, vol. 52, no. 4, pp. 639–672, 2000. [55] T. J. Murphy, R. W. Alexander, K. K. Griendling, M. S. Runge, and K. E. Bernstein, “Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor,” Nature, vol. 351, no. 6323, pp. 233–236, 1991. [56] I. H. Schulman, M. S. Zhou, and L. Raij, “Nitric oxide, angiotensin II, and reactive oxygen species in hypertension and atherogenesis,” Current Hypertension Reports, vol. 7, no. 1, pp. 61–67, 2005. [57] J. B. Laursen, S. Rajagopalan, Z. Galis, M. Tarpey, B. A. Free- man, and D. G. Harrison, “Role of superoxide in angiotensin II-induced but not catecholamine- induced hypertension,” Circulation, vol. 95, no. 3, pp. 588–593, 1997. [58] K. K. Griendling and G. A. FitzGerald, “Oxidative stress and cardiovascular injury: part I: basic mechanisms and in vivo monitoring of ROS,” Circulation, vol. 108, no. 16, pp. 1912– 1916, 2003. [59] B. Lasse`gue and R. E. Clempus, “Vascular NAD(P)H oxi- dases: speciﬁc features, expression, and regulation,” American Journal of Physiology, vol. 285, no. 2, pp. R277–R297, 2003. [60] K. K. Griendling, D. Sorescu, and M. Ushio-Fukai, “NAD(P)H oxidase: role in cardiovascular biology and disease,” Circulation Research, vol. 86, no. 5, pp. 494–501, 2000. [61] P. A. Barry-Lane, C. Patterson, M. Van Der Merwe et al., “p47phox is required for atherosclerotic lesion progression in ApoE mice (-/-),” Journal of Clinical Investigation, vol. 108, no. 10, pp. 1513–1522, 2001. [62] C. Viedt, U. Soto, H. I. Krieger-Brauer et al., “Diﬀerential activation of mitogen-activated protein kinases in smooth muscle cells by angiotensin II: involvement of p22phox and reactive oxygen species,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 4, pp. 940–948, 2000. [63] M. Ushio-Fukai, R. W. Alexander, M. Akers et al., “Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells,” Journal of Biological Chemistry, vol. 274, no. 32, pp. 22699–22704, 1999. [64] B. Schieﬀer, M. Luchtefeld, S. Braun, A. Hilﬁker, D. Hilﬁker- Kleiner, and H. Drexler, “Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction,” Circulation Research, vol. 87, no. 12, pp. 1195– 1201, 2000. [65] A. R. Simon, U. Rai, B. L. Fanburg, and B. H. Cochran, “Activation of the JAK-STAT pathway by reactive oxygen